Prasco Laboratories has entered an exclusive U.S. distribution and supply agreement with Shire for the authorized generic of Fosrenol Chewable Tablets.


Prasco Laboratories, Fosrenol Chewable Tablets, authorized generic, Shire, lanthanum carbonate, David Vucurevich, end-stage renal disease












































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks

Prasco, Shire sign pact for Fosrenol generic

October 17th, 2013

CINCINNATI – Prasco Laboratories has entered an exclusive U.S. distribution and supply agreement with Shire for the authorized generic of Fosrenol Chewable Tablets.

Prasco said Thursday that under the agreement, it will market lanthanum carbonate chewable tablets in dosages of 500 mg, 750 mg, and 1000 mg under the Prasco label in response to the first generic entrant.

"Today's announcement is the latest example of Prasco and Shire working together to continue providing high-quality prescription options to consumers," stated Prasco president and chief operating officer David Vucurevich. "Patients and customers alike benefit from Shire's commitment to maintaining the supply of brand-identical medication through the Prasco authorized generic business model."

Fosrenol is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD).

More Supplier News Breaks >>
Advertisement